Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 11/20 | 0.54 |
| ▸ | RPTOR | Q8N122 | 11/20 | 0.54 |
| ▸ | MLST8 | Q9BVC4 | 11/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 8/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20133717 | 0.93 | MTOR (0.58) | MTORRPTORMLST8GLS | |
| SCHEMBL20142476 | 0.91 | MTOR (0.59) | MTORRPTORMLST8GLSSLC6A2 | |
| SCHEMBL21360368 | 0.87 | MTOR (0.69) | MTORRPTORMLST8GLSSLC6A2 | |
| SCHEMBL20133757 | 0.87 | MTOR (0.62) | MTORRPTORMLST8GLSSLC6A2 | |
| SCHEMBL21340115 | 0.84 | MTOR (0.70) | MTORRPTORMLST8GLSSLC6A2 | |
| SCHEMBL20141628 | 0.83 | MTOR (0.64) | MTORRPTORMLST8GLS | |
| SCHEMBL20141015 | 0.80 | MTOR (0.74) | MTORRPTORMLST8GLS | |
| SCHEMBL20133716 | 0.79 | MTOR (0.66) | MTORRPTORMLST8GLS | |
| SCHEMBL20141507 | 0.79 | MTOR (0.58) | MTORRPTORMLST8GLS | |
| SCHEMBL22693194 | 0.79 | MTOR (0.58) | MTORRPTORMLST8GLSSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2020-07-02 | — | — | US | disclosed |
| EP-3538091-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| WO-2018089499-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 7/4885 |
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 7/4885 |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 7/4885 |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.